Our discovery that targeting druggable SWI/SNF remodeling activity reduces the chromatin binding of core TFs in NB presents a promising strategy to counteract the transcriptional dysregulation and malignant transformation associated with these core TFs. Here, SMARCA1 is linked to neuroblastoma.